Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients
A Phase Ib, Open-label, Multi-center, Dose-escalation and Expansion Study of an Orally Administered Combination of BKM120 Plus MEK162 in Adult Patients With Selected Advanced Solid Tumors
Status: Enrolling
Updated:  1/22/2018
Array BioPharma Investigative Site
mi
from
Toronto,
Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients
A Phase Ib, Open-label, Multi-center, Dose-escalation and Expansion Study of an Orally Administered Combination of BKM120 Plus MEK162 in Adult Patients With Selected Advanced Solid Tumors
Status: Enrolling
Updated: 1/22/2018
Array BioPharma Investigative Site
mi
from
Toronto,
Click here to add this to my saved trials
Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients
A Phase Ib, Open-label, Multi-center, Dose-escalation and Expansion Study of an Orally Administered Combination of BKM120 Plus MEK162 in Adult Patients With Selected Advanced Solid Tumors
Status: Enrolling
Updated:  1/22/2018
Memorial Sloan Kettering Cancer Center MSKCC (2)
mi
from
New York, NY
Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients
A Phase Ib, Open-label, Multi-center, Dose-escalation and Expansion Study of an Orally Administered Combination of BKM120 Plus MEK162 in Adult Patients With Selected Advanced Solid Tumors
Status: Enrolling
Updated: 1/22/2018
Memorial Sloan Kettering Cancer Center MSKCC (2)
mi
from
New York, NY
Click here to add this to my saved trials
Technology and Navigation to Improve Survivorship Care
Integrating Technology and Navigation to Improve Survivorship Care in Underserved Populations
Status: Enrolling
Updated:  1/22/2018
Lyndon B Johnson Hospital
mi
from
Houston, TX
Technology and Navigation to Improve Survivorship Care
Integrating Technology and Navigation to Improve Survivorship Care in Underserved Populations
Status: Enrolling
Updated: 1/22/2018
Lyndon B Johnson Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
Capecitabine With Digoxin for Metastatic Breast Cancer
Metronomic Capecitabine With Digoxin for Metastatic Breast Cancer Progressing After Anthracycline and Taxane Treatment
Status: Enrolling
Updated:  1/22/2018
Western Regional Medical Center, Inc
mi
from
Goodyear, AZ
Capecitabine With Digoxin for Metastatic Breast Cancer
Metronomic Capecitabine With Digoxin for Metastatic Breast Cancer Progressing After Anthracycline and Taxane Treatment
Status: Enrolling
Updated: 1/22/2018
Western Regional Medical Center, Inc
mi
from
Goodyear, AZ
Click here to add this to my saved trials
(PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma
Platinum-Gemcitabine-Avastin (PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma
Status: Enrolling
Updated:  1/22/2018
Western Regional Medical Center, Inc
mi
from
Goodyear, AZ
(PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma
Platinum-Gemcitabine-Avastin (PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma
Status: Enrolling
Updated: 1/22/2018
Western Regional Medical Center, Inc
mi
from
Goodyear, AZ
Click here to add this to my saved trials
A Study of Vantictumab (OMP-18R5) in Combination With Paclitaxel in Locally Recurrent or Metastatic Breast Cancer
A Phase 1b Dose Escalation Study of Vantictumab (OMP-18R5) in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  1/22/2018
Cedars-Sinai Medical Center/Samuel Oschin Comprehensive Cancer institute
mi
from
Los Angeles, CA
A Study of Vantictumab (OMP-18R5) in Combination With Paclitaxel in Locally Recurrent or Metastatic Breast Cancer
A Phase 1b Dose Escalation Study of Vantictumab (OMP-18R5) in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 1/22/2018
Cedars-Sinai Medical Center/Samuel Oschin Comprehensive Cancer institute
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study of Vantictumab (OMP-18R5) in Combination With Paclitaxel in Locally Recurrent or Metastatic Breast Cancer
A Phase 1b Dose Escalation Study of Vantictumab (OMP-18R5) in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  1/22/2018
University of Colorado Cancer Center
mi
from
Aurora, CO
A Study of Vantictumab (OMP-18R5) in Combination With Paclitaxel in Locally Recurrent or Metastatic Breast Cancer
A Phase 1b Dose Escalation Study of Vantictumab (OMP-18R5) in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 1/22/2018
University of Colorado Cancer Center
mi
from
Aurora, CO
Click here to add this to my saved trials
A Study of Vantictumab (OMP-18R5) in Combination With Paclitaxel in Locally Recurrent or Metastatic Breast Cancer
A Phase 1b Dose Escalation Study of Vantictumab (OMP-18R5) in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  1/22/2018
Texas Oncology-Baylor Charles A. Sammons Cancer Center
mi
from
Dallas, TX
A Study of Vantictumab (OMP-18R5) in Combination With Paclitaxel in Locally Recurrent or Metastatic Breast Cancer
A Phase 1b Dose Escalation Study of Vantictumab (OMP-18R5) in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 1/22/2018
Texas Oncology-Baylor Charles A. Sammons Cancer Center
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study of Vantictumab (OMP-18R5) in Combination With Paclitaxel in Locally Recurrent or Metastatic Breast Cancer
A Phase 1b Dose Escalation Study of Vantictumab (OMP-18R5) in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated:  1/22/2018
Texas Oncology-Tyler
mi
from
Tyler, TX
A Study of Vantictumab (OMP-18R5) in Combination With Paclitaxel in Locally Recurrent or Metastatic Breast Cancer
A Phase 1b Dose Escalation Study of Vantictumab (OMP-18R5) in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Breast Cancer
Status: Enrolling
Updated: 1/22/2018
Texas Oncology-Tyler
mi
from
Tyler, TX
Click here to add this to my saved trials
A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer
A Phase 1b Dose Escalation Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer
Status: Enrolling
Updated:  1/22/2018
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer
A Phase 1b Dose Escalation Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer
Status: Enrolling
Updated: 1/22/2018
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer
A Phase 1b Dose Escalation Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer
Status: Enrolling
Updated:  1/22/2018
University of Colorado Hospital Anschutz Cancer Pavillion
mi
from
Aurora, CO
A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer
A Phase 1b Dose Escalation Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer
Status: Enrolling
Updated: 1/22/2018
University of Colorado Hospital Anschutz Cancer Pavillion
mi
from
Aurora, CO
Click here to add this to my saved trials
A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer
A Phase 1b Dose Escalation Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer
Status: Enrolling
Updated:  1/22/2018
Indiana University Simon Cancer Center
mi
from
Indianapolis, IN
A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer
A Phase 1b Dose Escalation Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer
Status: Enrolling
Updated: 1/22/2018
Indiana University Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer
A Phase 1b Dose Escalation Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer
Status: Enrolling
Updated:  1/22/2018
Fox Chase Cancer Center
mi
from
Philadelphia, PA
A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer
A Phase 1b Dose Escalation Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer
Status: Enrolling
Updated: 1/22/2018
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer
A Phase 1b Dose Escalation Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer
Status: Enrolling
Updated:  1/22/2018
Vanderbilt University Medical Center
mi
from
Nashville, TN
A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer
A Phase 1b Dose Escalation Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer
Status: Enrolling
Updated: 1/22/2018
Vanderbilt University Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Cancer Patients Diagnosed With Unsuspected Venous Thromboembolism (VTE) on Routine Computed Tomography (CT) Scans
A Prospective Study of Cancer Patients Diagnosed With Unsuspected Venous Thromboembolism (VTE) on Routine Computed Tomography (CT) Scans
Status: Enrolling
Updated:  1/22/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Cancer Patients Diagnosed With Unsuspected Venous Thromboembolism (VTE) on Routine Computed Tomography (CT) Scans
A Prospective Study of Cancer Patients Diagnosed With Unsuspected Venous Thromboembolism (VTE) on Routine Computed Tomography (CT) Scans
Status: Enrolling
Updated: 1/22/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Dose Escalation Study of OMP-54F28 in Combination With Paclitaxel and Carboplatin in Patients With Recurrent Platinum-Sensitive Ovarian Cancer
A Phase 1b Dose Escalation Study of OMP-54F28 in Combination With Paclitaxel and Carboplatin in Patients With Recurrent Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated:  1/22/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Dose Escalation Study of OMP-54F28 in Combination With Paclitaxel and Carboplatin in Patients With Recurrent Platinum-Sensitive Ovarian Cancer
A Phase 1b Dose Escalation Study of OMP-54F28 in Combination With Paclitaxel and Carboplatin in Patients With Recurrent Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated: 1/22/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Dose Escalation Study of OMP-54F28 in Combination With Paclitaxel and Carboplatin in Patients With Recurrent Platinum-Sensitive Ovarian Cancer
A Phase 1b Dose Escalation Study of OMP-54F28 in Combination With Paclitaxel and Carboplatin in Patients With Recurrent Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated:  1/22/2018
OU Medical Center Laboratory
mi
from
Oklahoma City, OK
Dose Escalation Study of OMP-54F28 in Combination With Paclitaxel and Carboplatin in Patients With Recurrent Platinum-Sensitive Ovarian Cancer
A Phase 1b Dose Escalation Study of OMP-54F28 in Combination With Paclitaxel and Carboplatin in Patients With Recurrent Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated: 1/22/2018
OU Medical Center Laboratory
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Dose Escalation Study of OMP-54F28 in Combination With Paclitaxel and Carboplatin in Patients With Recurrent Platinum-Sensitive Ovarian Cancer
A Phase 1b Dose Escalation Study of OMP-54F28 in Combination With Paclitaxel and Carboplatin in Patients With Recurrent Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated:  1/22/2018
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Dose Escalation Study of OMP-54F28 in Combination With Paclitaxel and Carboplatin in Patients With Recurrent Platinum-Sensitive Ovarian Cancer
A Phase 1b Dose Escalation Study of OMP-54F28 in Combination With Paclitaxel and Carboplatin in Patients With Recurrent Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated: 1/22/2018
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Dose Escalation Study of OMP-54F28 in Combination With Paclitaxel and Carboplatin in Patients With Recurrent Platinum-Sensitive Ovarian Cancer
A Phase 1b Dose Escalation Study of OMP-54F28 in Combination With Paclitaxel and Carboplatin in Patients With Recurrent Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated:  1/22/2018
University of Pennsylvania Health System
mi
from
Philadelphia, PA
Dose Escalation Study of OMP-54F28 in Combination With Paclitaxel and Carboplatin in Patients With Recurrent Platinum-Sensitive Ovarian Cancer
A Phase 1b Dose Escalation Study of OMP-54F28 in Combination With Paclitaxel and Carboplatin in Patients With Recurrent Platinum-Sensitive Ovarian Cancer
Status: Enrolling
Updated: 1/22/2018
University of Pennsylvania Health System
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Open Label Phase Two Trial of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Symptomatic Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Bone Metastasis
Open Label Phase Two Trial of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Symptomatic Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Bone Metastasis
Status: Enrolling
Updated:  1/22/2018
Chesapeake Urology Research Associates
mi
from
Towson, MD
Open Label Phase Two Trial of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Symptomatic Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Bone Metastasis
Open Label Phase Two Trial of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Symptomatic Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Bone Metastasis
Status: Enrolling
Updated: 1/22/2018
Chesapeake Urology Research Associates
mi
from
Towson, MD
Click here to add this to my saved trials
Open Label Phase Two Trial of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Symptomatic Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Bone Metastasis
Open Label Phase Two Trial of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Symptomatic Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Bone Metastasis
Status: Enrolling
Updated:  1/22/2018
Urology Cancer Center & GU Research Network
mi
from
Omaha, NE
Open Label Phase Two Trial of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Symptomatic Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Bone Metastasis
Open Label Phase Two Trial of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Symptomatic Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Bone Metastasis
Status: Enrolling
Updated: 1/22/2018
Urology Cancer Center & GU Research Network
mi
from
Omaha, NE
Click here to add this to my saved trials
Open Label Phase Two Trial of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Symptomatic Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Bone Metastasis
Open Label Phase Two Trial of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Symptomatic Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Bone Metastasis
Status: Enrolling
Updated:  1/22/2018
Associated Medical Professionals
mi
from
Syracuse, NY
Open Label Phase Two Trial of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Symptomatic Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Bone Metastasis
Open Label Phase Two Trial of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Symptomatic Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Bone Metastasis
Status: Enrolling
Updated: 1/22/2018
Associated Medical Professionals
mi
from
Syracuse, NY
Click here to add this to my saved trials
Open Label Phase Two Trial of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Symptomatic Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Bone Metastasis
Open Label Phase Two Trial of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Symptomatic Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Bone Metastasis
Status: Enrolling
Updated:  1/22/2018
Oregon Urology Institute
mi
from
Springfield, OR
Open Label Phase Two Trial of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Symptomatic Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Bone Metastasis
Open Label Phase Two Trial of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Symptomatic Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Bone Metastasis
Status: Enrolling
Updated: 1/22/2018
Oregon Urology Institute
mi
from
Springfield, OR
Click here to add this to my saved trials
Open Label Phase Two Trial of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Symptomatic Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Bone Metastasis
Open Label Phase Two Trial of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Symptomatic Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Bone Metastasis
Status: Enrolling
Updated:  1/22/2018
Carolina Urologic Research Center
mi
from
Myrtle Beach, SC
Open Label Phase Two Trial of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Symptomatic Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Bone Metastasis
Open Label Phase Two Trial of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Symptomatic Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Bone Metastasis
Status: Enrolling
Updated: 1/22/2018
Carolina Urologic Research Center
mi
from
Myrtle Beach, SC
Click here to add this to my saved trials
Preoperative Rehabilitation During Neoadjuvant Therapy for Pancreatic Cancer
Preoperative Rehabilitation During Neoadjuvant Therapy for Pancreatic Cancer: A Pilot Study
Status: Enrolling
Updated:  1/22/2018
University of Houston
mi
from
Houston, TX
Preoperative Rehabilitation During Neoadjuvant Therapy for Pancreatic Cancer
Preoperative Rehabilitation During Neoadjuvant Therapy for Pancreatic Cancer: A Pilot Study
Status: Enrolling
Updated: 1/22/2018
University of Houston
mi
from
Houston, TX
Click here to add this to my saved trials
Preoperative Rehabilitation During Neoadjuvant Therapy for Pancreatic Cancer
Preoperative Rehabilitation During Neoadjuvant Therapy for Pancreatic Cancer: A Pilot Study
Status: Enrolling
Updated:  1/22/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Preoperative Rehabilitation During Neoadjuvant Therapy for Pancreatic Cancer
Preoperative Rehabilitation During Neoadjuvant Therapy for Pancreatic Cancer: A Pilot Study
Status: Enrolling
Updated: 1/22/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy
Intra-mammary Distribution of Transdermal Telapristone Versus Oral Telapristone: A Randomized Window Trial in Women Undergoing Mastectomy
Status: Enrolling
Updated:  1/22/2018
Cedars-Sinai Medical Center
mi
from
West Hollywood, CA
Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy
Intra-mammary Distribution of Transdermal Telapristone Versus Oral Telapristone: A Randomized Window Trial in Women Undergoing Mastectomy
Status: Enrolling
Updated: 1/22/2018
Cedars-Sinai Medical Center
mi
from
West Hollywood, CA
Click here to add this to my saved trials
Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy
Intra-mammary Distribution of Transdermal Telapristone Versus Oral Telapristone: A Randomized Window Trial in Women Undergoing Mastectomy
Status: Enrolling
Updated:  1/22/2018
Northwestern University
mi
from
Chicago, IL
Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy
Intra-mammary Distribution of Transdermal Telapristone Versus Oral Telapristone: A Randomized Window Trial in Women Undergoing Mastectomy
Status: Enrolling
Updated: 1/22/2018
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy
Intra-mammary Distribution of Transdermal Telapristone Versus Oral Telapristone: A Randomized Window Trial in Women Undergoing Mastectomy
Status: Enrolling
Updated:  1/22/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy
Intra-mammary Distribution of Transdermal Telapristone Versus Oral Telapristone: A Randomized Window Trial in Women Undergoing Mastectomy
Status: Enrolling
Updated: 1/22/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy
Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy (Taxotere, Trastuzumab and Pertuzumab) in Patients With HER2-positive and ER-Positive Breast Cancer (NeoHTTP Study)
Status: Enrolling
Updated:  1/22/2018
Western Regional Medical Center, Inc
mi
from
Goodyear, AZ
Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy
Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy (Taxotere, Trastuzumab and Pertuzumab) in Patients With HER2-positive and ER-Positive Breast Cancer (NeoHTTP Study)
Status: Enrolling
Updated: 1/22/2018
Western Regional Medical Center, Inc
mi
from
Goodyear, AZ
Click here to add this to my saved trials
Rivaroxaban Utilization for Treatment and Prevention of Thromboembolism in Cancer Patients: Experience at a Comprehensive Cancer Center
Retrospective Study: Rivaroxaban Utilization for Treatment and Prevention of Thromboembolism in Cancer Patients: Experience at a Comprehensive Cancer Center
Status: Enrolling
Updated:  1/22/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Rivaroxaban Utilization for Treatment and Prevention of Thromboembolism in Cancer Patients: Experience at a Comprehensive Cancer Center
Retrospective Study: Rivaroxaban Utilization for Treatment and Prevention of Thromboembolism in Cancer Patients: Experience at a Comprehensive Cancer Center
Status: Enrolling
Updated: 1/22/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Taxoprexin Plus Carboplatin Treatment for Advanced Lung Cancer
A Phase III, Randomized, Study of Weekly Taxoprexin Plus Carboplatin Versus Paclitaxel Plus Carboplatin as First Line Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/22/2018
US Oncology
mi
from
Dallas, TX
Taxoprexin Plus Carboplatin Treatment for Advanced Lung Cancer
A Phase III, Randomized, Study of Weekly Taxoprexin Plus Carboplatin Versus Paclitaxel Plus Carboplatin as First Line Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/22/2018
US Oncology
mi
from
Dallas, TX
Click here to add this to my saved trials
Depression Treatment and Screening in Ovarian Cancer Patients
Depression Treatment and Screening in Ovarian Cancer Patients
Status: Enrolling
Updated:  1/22/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Depression Treatment and Screening in Ovarian Cancer Patients
Depression Treatment and Screening in Ovarian Cancer Patients
Status: Enrolling
Updated: 1/22/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer
T Cell-Reduced Unrelated Donor Allogeneic Peripheral Blood Stem Cell Transplantation With Pentostatin and Low-Dose Total Body Irradiation
Status: Enrolling
Updated:  1/22/2018
UNMC Eppley Cancer Center at the University of Nebraska Medical Center
mi
from
Omaha, NE
Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer
T Cell-Reduced Unrelated Donor Allogeneic Peripheral Blood Stem Cell Transplantation With Pentostatin and Low-Dose Total Body Irradiation
Status: Enrolling
Updated: 1/22/2018
UNMC Eppley Cancer Center at the University of Nebraska Medical Center
mi
from
Omaha, NE
Click here to add this to my saved trials
Use of the Contura™ Catheter in Intermediate-Risk, Pathological Stage 0, I, or II (Up to 3.0 cm) Breast Cancer Patients
Registry Study of the Contura™ Multi-Lumen Balloon (MLB) Applicator for Accelerated Partial Breast Irradiation in Intermediate-Risk, Pathological Stage 0, I, or II (Up to 3.0 cm) Breast Cancer Patients
Status: Enrolling
Updated:  1/23/2018
Cancer Center of Irvine
mi
from
Irvine, CA
Use of the Contura™ Catheter in Intermediate-Risk, Pathological Stage 0, I, or II (Up to 3.0 cm) Breast Cancer Patients
Registry Study of the Contura™ Multi-Lumen Balloon (MLB) Applicator for Accelerated Partial Breast Irradiation in Intermediate-Risk, Pathological Stage 0, I, or II (Up to 3.0 cm) Breast Cancer Patients
Status: Enrolling
Updated: 1/23/2018
Cancer Center of Irvine
mi
from
Irvine, CA
Click here to add this to my saved trials
Use of the Contura™ Catheter to Deliver Accelerated Partial Breast Irradiation to "Low-risk" Breast Cancer Patients
A Multi-Site, Prospective, Non-Randomized Study of the Contura™ Multi-Lumen Balloon (MLB) Catheter to Deliver Accelerated Partial Breast Irradiation: Analysis of Dosimetry, Local Tumor Control, Cosmetic Outcome, and Toxicity
Status: Enrolling
Updated:  1/23/2018
Cancer Center of Irvine
mi
from
Irvine, CA
Use of the Contura™ Catheter to Deliver Accelerated Partial Breast Irradiation to "Low-risk" Breast Cancer Patients
A Multi-Site, Prospective, Non-Randomized Study of the Contura™ Multi-Lumen Balloon (MLB) Catheter to Deliver Accelerated Partial Breast Irradiation: Analysis of Dosimetry, Local Tumor Control, Cosmetic Outcome, and Toxicity
Status: Enrolling
Updated: 1/23/2018
Cancer Center of Irvine
mi
from
Irvine, CA
Click here to add this to my saved trials
Evaluation of Balloon-based Cryoablation of Human Esophageal Epithelium
Evaluation of Balloon-based Cryoablation of Human Esophageal Epithelium
Status: Enrolling
Updated:  1/23/2018
University of Southern California
mi
from
Los Angeles, CA
Evaluation of Balloon-based Cryoablation of Human Esophageal Epithelium
Evaluation of Balloon-based Cryoablation of Human Esophageal Epithelium
Status: Enrolling
Updated: 1/23/2018
University of Southern California
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Evaluation of Balloon-based Cryoablation of Human Esophageal Epithelium
Evaluation of Balloon-based Cryoablation of Human Esophageal Epithelium
Status: Enrolling
Updated:  1/23/2018
University of Rochester
mi
from
Rochester, NY
Evaluation of Balloon-based Cryoablation of Human Esophageal Epithelium
Evaluation of Balloon-based Cryoablation of Human Esophageal Epithelium
Status: Enrolling
Updated: 1/23/2018
University of Rochester
mi
from
Rochester, NY
Click here to add this to my saved trials
Evaluation of Balloon-based Cryoablation of Human Esophageal Epithelium
Evaluation of Balloon-based Cryoablation of Human Esophageal Epithelium
Status: Enrolling
Updated:  1/23/2018
University of Pittsburgh
mi
from
Pittsburgh, PA
Evaluation of Balloon-based Cryoablation of Human Esophageal Epithelium
Evaluation of Balloon-based Cryoablation of Human Esophageal Epithelium
Status: Enrolling
Updated: 1/23/2018
University of Pittsburgh
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Evaluation of Balloon-based Cryoablation of Human Esophageal Epithelium
Evaluation of Balloon-based Cryoablation of Human Esophageal Epithelium
Status: Enrolling
Updated:  1/23/2018
AMC
mi
from
Amsterdam,
Evaluation of Balloon-based Cryoablation of Human Esophageal Epithelium
Evaluation of Balloon-based Cryoablation of Human Esophageal Epithelium
Status: Enrolling
Updated: 1/23/2018
AMC
mi
from
Amsterdam,
Click here to add this to my saved trials
Sorafenib and Yttrium-90 Glass Microspheres for Advanced Hepatocellular Carcinoma (HCC)
A Phase II Study of Sorafenib and Yttrium-90 Glass Microspheres for Advanced Hepatocellular Carcinoma, BCLC Stage C
Status: Enrolling
Updated:  1/23/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Sorafenib and Yttrium-90 Glass Microspheres for Advanced Hepatocellular Carcinoma (HCC)
A Phase II Study of Sorafenib and Yttrium-90 Glass Microspheres for Advanced Hepatocellular Carcinoma, BCLC Stage C
Status: Enrolling
Updated: 1/23/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients
Phase Ib Trial of Two Folate Binding Protein (FBP) Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients
Status: Enrolling
Updated:  1/23/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients
Phase Ib Trial of Two Folate Binding Protein (FBP) Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients
Status: Enrolling
Updated: 1/23/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
MEK Inhibitor MEK162 in Combination With Leucovorin Calcium, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Metastatic Colorectal Cancer
A Phase I Clinical Trial of MEK162 in Combination With FOLFOX in Patients With Advanced Metastatic Colorectal Cancer Who Failed Prior Standard Therapy
Status: Enrolling
Updated:  1/23/2018
City of Hope Medical Center
mi
from
Duarte, CA
MEK Inhibitor MEK162 in Combination With Leucovorin Calcium, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Metastatic Colorectal Cancer
A Phase I Clinical Trial of MEK162 in Combination With FOLFOX in Patients With Advanced Metastatic Colorectal Cancer Who Failed Prior Standard Therapy
Status: Enrolling
Updated: 1/23/2018
City of Hope Medical Center
mi
from
Duarte, CA
Click here to add this to my saved trials
IMPACT 2: Randomized Study Evaluating Molecular Profiling and Targeted Agents in Metastatic Cancer
Randomized Study Evaluating Molecular Profiling and Targeted Agents in Metastatic Cancer: Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT 2)
Status: Enrolling
Updated:  1/23/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
IMPACT 2: Randomized Study Evaluating Molecular Profiling and Targeted Agents in Metastatic Cancer
Randomized Study Evaluating Molecular Profiling and Targeted Agents in Metastatic Cancer: Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT 2)
Status: Enrolling
Updated: 1/23/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Home-Based Lymphedema Care Program (HBLCP) in Improving Lymphedema Self-Care in Head and Neck Cancer Survivors
Development and Pilot Testing of a Home-Based Program for Head and Neck Cancer Survivors With Lymphedema
Status: Enrolling
Updated:  1/23/2018
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Home-Based Lymphedema Care Program (HBLCP) in Improving Lymphedema Self-Care in Head and Neck Cancer Survivors
Development and Pilot Testing of a Home-Based Program for Head and Neck Cancer Survivors With Lymphedema
Status: Enrolling
Updated: 1/23/2018
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Irinotecan and Capecitabine as Second-line Treatment for Advanced/Metastatic Biliary Tract Cancers
A Phase II Trial of Combination Irinotecan and Capecitabine as Second-Line Treatment for Patients With Locally Advanced/Metastatic Biliary Tract Cancers Who Progressed or Intolerant to Front-Line Gemcitabine and Platinum Combination
Status: Enrolling
Updated:  1/23/2018
Universtiy of New Mexico Cancer Center
mi
from
Albuquerque, NM
Irinotecan and Capecitabine as Second-line Treatment for Advanced/Metastatic Biliary Tract Cancers
A Phase II Trial of Combination Irinotecan and Capecitabine as Second-Line Treatment for Patients With Locally Advanced/Metastatic Biliary Tract Cancers Who Progressed or Intolerant to Front-Line Gemcitabine and Platinum Combination
Status: Enrolling
Updated: 1/23/2018
Universtiy of New Mexico Cancer Center
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Sodium Stibogluconate and Interferon in Treating Patients With Advanced Solid Tumors, Lymphoma, or Myeloma
Phase I Evaluation of Sodium Stibogluconate in Combination With Interferon α-2b for Solid Tumors, Lymphoma or Myeloma
Status: Enrolling
Updated:  1/24/2018
Cleveland Clinic Taussig Cancer Center
mi
from
Cleveland, OH
Sodium Stibogluconate and Interferon in Treating Patients With Advanced Solid Tumors, Lymphoma, or Myeloma
Phase I Evaluation of Sodium Stibogluconate in Combination With Interferon α-2b for Solid Tumors, Lymphoma or Myeloma
Status: Enrolling
Updated: 1/24/2018
Cleveland Clinic Taussig Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Performance Evaluation of the AMS CONTINUUM™ Device
Performance Evaluation of the AMS CONTINUUM™ Device in Facilitating Vesico-Urethral Anastomosis Following a Radical Prostatectomy
Status: Enrolling
Updated:  1/24/2018
Arkansas Urology
mi
from
Little Rock, AR
Performance Evaluation of the AMS CONTINUUM™ Device
Performance Evaluation of the AMS CONTINUUM™ Device in Facilitating Vesico-Urethral Anastomosis Following a Radical Prostatectomy
Status: Enrolling
Updated: 1/24/2018
Arkansas Urology
mi
from
Little Rock, AR
Click here to add this to my saved trials
Performance Evaluation of the AMS CONTINUUM™ Device
Performance Evaluation of the AMS CONTINUUM™ Device in Facilitating Vesico-Urethral Anastomosis Following a Radical Prostatectomy
Status: Enrolling
Updated:  1/24/2018
Center for Urology
mi
from
Rochester, NY
Performance Evaluation of the AMS CONTINUUM™ Device
Performance Evaluation of the AMS CONTINUUM™ Device in Facilitating Vesico-Urethral Anastomosis Following a Radical Prostatectomy
Status: Enrolling
Updated: 1/24/2018
Center for Urology
mi
from
Rochester, NY
Click here to add this to my saved trials
Performance Evaluation of the AMS CONTINUUM™ Device
Performance Evaluation of the AMS CONTINUUM™ Device in Facilitating Vesico-Urethral Anastomosis Following a Radical Prostatectomy
Status: Enrolling
Updated:  1/24/2018
Urology Clinics of North Texas
mi
from
Dallas, TX
Performance Evaluation of the AMS CONTINUUM™ Device
Performance Evaluation of the AMS CONTINUUM™ Device in Facilitating Vesico-Urethral Anastomosis Following a Radical Prostatectomy
Status: Enrolling
Updated: 1/24/2018
Urology Clinics of North Texas
mi
from
Dallas, TX
Click here to add this to my saved trials